Separation of precursor T cells and Ig-secreting B cells from the large lymphocytic cells of human tonsil

Agrapart, Monique; Durandy, Anne; Griscelli, C; Daguillard, F

doi:10.1016/0008-8749(77)90159-9

Cited by 5 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Excessive production of these inflammatory cytokines causes a phenomenon termed the cytokine storm, which leads to the development and exacerbation of acute respiratory distress syndrome (ARDS) or extrapulmonary multiple organ failure. Many cytokines and chemokines have been implicated in the pathogenesis of this hyperinflammatory response [ 6 ]. This cytokine profile resembles secondary hemophagocytic lymphohistiocytosis (sHLH), a hyperinflammatory syndrome resulting in fulminant multiorgan failure.…”

Section: Introductionmentioning

confidence: 99%

The Safety and Efficacy of Anakinra, an Interleukin-1 Antagonist in Severe Cases of COVID-19: A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

This study aims to assess anakinra's safety and efficacy for treating severe coronavirus disease 2019 (COVID-19). Numerous electronic databases were searched and finally 15 studies with a total of 3,530 patients, 757 in the anakinra arm, 1,685 in the control arm were included. The pooled adjusted odds ratio (OR) for mortality in the treatment arm was 0.34 (95% confidence interval [CI], 0.21 - 0.54, I 2 = 48%), indicating a significant association between anakinra and mortality. A significant association was found regarding mechanical ventilation requirements in anakinra group compared to the control group OR, 0.68 (95% CI, 0.49 - 0.95, I 2 = 50%). For the safety of anakinra, we evaluated thromboembolism risk and liver transaminases elevation. Thromboembolism risk was OR, 1.59 (95% CI, 0.65 - 3.91, I 2 = 0%) and elevation in liver transaminases with OR was 1.35 (95% CI, 0.61 - 3.03, I 2 = 76%). Both were not statistically significant over the control group. Anakinra is beneficial in lowering mortality in COVID-19 patients. However, these non-significant differences in the safety profile between the anakinra and control groups may have been the result of baseline characteristics of the intervention group, and further studies are essential in evaluating anakinra's safety profile.

show abstract

Section: Introductionmentioning

confidence: 99%

The Safety and Efficacy of Anakinra, an Interleukin-1 Antagonist in Severe Cases of COVID-19: A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Excessive production of these in ammatory cytokines causes a phenomenon termed the cytokine storm, which leads to the development and exacerbation of ARDS or extrapulmonary multiple organ failure. Many cytokines and chemokines have been implicated in the pathogenesis of this hyperin ammatory response [6]. This cytokine pro le resembles secondary hemophagocytic lymphohistiocytosis (sHLH), a hyperin ammatory syndrome resulting in fulminant multiorgan failure.…”

Section: Introductionmentioning

confidence: 99%

The Safety and Efficacy of the Interleukin-1 Antagonist Anakinra in Severe Cases of COVID-19- A Systematic Review and Meta-analysis.

Somagutta

Pormento

Hamid

et al. 2020

Preprint

View full text Add to dashboard Cite

This study aims to assess anakinra's safety and efficacy for treating severe coronavirus disease in 2019 (COVID-19). PubMed, Google Scholar, Cochrane Library, Embase, Scopus, medRxiv, and bioRxiv were searched. Three retrospective studies and five case series involving 3,274 adult patients with severe COVID-19 were included, 621 treated with anakinra (whether administered alone or in combination with other drugs) and 1,565 in the control group arm. All-cause mortality of severe COVID-19 patients among the anakinra group was 20% (16/81), which was lower than that in the control group (65%; 39/60). The difference was statistically significant [hazard ratio (HR) = 0.13, 95% confidence interval (CI) 0.06–0.29, I2= 0%]. The mechanical ventilation requirement with OR 0.57 (0.11-2.84, I2=87%) was not significantly better compared to the control group. For the safety of anakinra, we evaluated thromboembolism risk and liver enzyme elevation. Thromboembolism risk with OR: 1.48 (0.55- 3.99, I2=0%) and elevation in liver transaminases with OR 0.67 (0.11-3.93, I2=66%) were not statistically significant over the control group. However, these non-significant differences between the anakinra and control groups may have been the result of baseline characteristics of the intervention group, and further studies are essential in evaluating anakinra's safety profile.

show abstract

Studies on the cell-mediated immune response of tonsillar lymphocytes with regard to the clinical course and patient's age

Sugiyama

Sasaki

Nakai

et al. 1982

International Journal of Pediatric Otorhinolaryngology

View full text Add to dashboard Cite

Separation of precursor T cells and Ig-secreting B cells from the large lymphocytic cells of human tonsil

Cited by 5 publications

References 8 publications

The Safety and Efficacy of Anakinra, an Interleukin-1 Antagonist in Severe Cases of COVID-19: A Systematic Review and Meta-Analysis

The Safety and Efficacy of Anakinra, an Interleukin-1 Antagonist in Severe Cases of COVID-19: A Systematic Review and Meta-Analysis

The Safety and Efficacy of the Interleukin-1 Antagonist Anakinra in Severe Cases of COVID-19- A Systematic Review and Meta-analysis.

Studies on the cell-mediated immune response of tonsillar lymphocytes with regard to the clinical course and patient's age

Contact Info

Product

Resources

About